Cardiovascular and all‐cause mortality in patients with intermittent claudication and critical limb ischaemia. BJS 2018; 105: 252-261.
Published: 8th November 2017
Authors: S. T. W. van Haelst, C. Koopman, H. M. den Ruijter, F. L. Moll, F. L. Visseren, I. Vaartjes et al.
The aim of this study was to evaluate absolute mortality risks and to determine whether changes in mortality risk occurred in patients with intermittent claudication (IC) or critical limb ischaemia (CLI) in the Netherlands between 1998 and 2010.
Data for patients treated between 1998 and 2010 were obtained from Dutch nationwide registers: the Hospital Discharge Register, Population Register and Cause of Death Register. The registers were used to obtain information regarding IC and CLI hospitalizations, co‐morbidities, demographic factors, and date and cause of death. The cohort was split into two time intervals for comparison: 1998–2004 (period 1) and 2005–2010 (period 2). Thirty‐day mortality was excluded to eliminate per‐admission complications. One‐ and 5‐year cardiovascular and all‐cause mortality rates were compared with those of a representative sample of the general Dutch population (28 494 persons) by Cox proportional hazards models.
Some 47 548 patients were included, 34 078 with IC and 13 470 with CLI. In patients with IC, the age‐adjusted 5‐year mortality risk for cardiovascular disease decreased significantly in period 2 (14·1 per cent) compared with that in period 1 (16·1 per cent) in men only (5‐year adjusted hazard ratio (HR) 0·76, 95 per cent c.i. 0·69 to 0·83;
The risk of premature death in patients with IC and CLI declined significantly in the Netherlands, in a sex‐specific manner, over the period from 1998 to 2010. The absolute risk of cardiovascular mortality remains high in these patients.Full text
You may also be interested in
Authors: K. Heikkila, I. M. Loftus, D. C. Mitchell, A. S. Johal, S. Waton, D. A. Cromwell et al.
Notes: lower than previously estimated
Cost‐effectiveness of population‐based vascular disease screening and intervention in men from the Viborg Vascular (VIVA) trial.
Authors: R. Søgaard, J. S. Lindholt
Notes: Highly cost effective
Five‐year follow‐up of a randomized clinical trial comparing open surgery, foam sclerotherapy and endovenous laser ablation for great saphenous varicose veins. BJS 2018; 105: 686-691.
Authors: S. Vähäaho, K. Halmesmäki, A. Albäck, E. Saarinen, M. Venermo
Notes: More foam recurrences
Eight‐year follow‐up of a randomized clinical trial comparing ultrasound‐guided foam sclerotherapy with surgical stripping of the great saphenous vein. BJS 2018; 105: 692-698.
Authors: Y. L. Lam, J. A. Lawson, I. M. Toonder, N. H. Shadid, A. Sommer, M. Veenstra et al.
Notes: Surgery better
Authors: M. J. Sweeting, P. Ulug, J. Roy, R. Hultgren, R. Indrakusuma, R. Balm et al.
Notes: Not much help
Follow‐up after endovascular aortic aneurysm repair can be stratified based on first postoperative imaging. BJS 2018; 105: 709-718.
Authors: H. Baderkhan, O. Haller, A. Wanhainen, M. Björck, K. Mani
Notes: Short sealing zones spell trouble
Risk of major amputation in patients with intermittent claudication undergoing early revascularization. BJS 2018; 105: 699-708.
Authors: J. Golledge, J. V. Moxon, S. Rowbotham, J. Pinchbeck, L. Yip, R. Velu et al.
Notes: Early revascularization associated with amputation
Authors: R. E. Clough, R. Spear, K. Van Calster, A. Hertault, R. Azzaoui, J. Sobocinski et al.
Notes: Encouraging results in expert hands
Authors: N. Rudarakanchana, M. P. Jenkins
Notes: Formidable challenge
Cellular and molecular imaging of the arteries in the age of precision medicine. BJS 2018; 105: 311-312.
Authors: R. O. Forsythe, D. E. Newby
Comparative analysis of the outcomes of elective abdominal aortic aneurysm repair in England and Sweden. BJS 2018; 105: 520-528.
Authors: A. Karthikesalingam, M. J. Grima, P. J. Holt, A. Vidal‐Diez, M. M. Thompson, A. Wanhainen et al.
Notes: Improving in England
Participation in bowel screening among men attending abdominal aortic aneurysm screening. BJS 2018; 105: 529-534.
Authors: A. J. Quyn, C. G. Fraser, J. Rodger, A. Digan, A. S. Anderson, R. J. C. Steele et al.
Notes: Maximizing screening benefits